Acylsulfonamide KAT6A inhibitors

US12428379B2 · kind B2 · utility

Assignees

• Olema Pharmaceuticals, Inc. · US
• Aurigene Oncology Limited · IN

Inventors

• Brian Hearn · San Francisco, US
• David C. Myles · Kensington, US
• Reena Chawla · Tucson, US
• David Yeghikyan · Fremont, US
• Chandregowda Venkateshappa · Noida, IN
• Susanta Samajdar · Savanuru, IN
• Kalisankar Bera · Kanchinakote, IN
• Suraj Tatyasaheb Gore · Ashti, IN
• Raymond Ng · San Ramon, US

Key dates

• Filing date: Dec 23, 2024
• Grant date: Sep 30, 2025
• Expiry date: Dec 23, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.